Liver function breath tests for differentiation of steatohepatitis from simple fatty liver in patients with nonalcoholic fatty liver disease

Journal of Clinical Gastroenterology

Volumn 48, Issue 1, 2014, Pages 59-65

  Tribonias, George ^a   Margariti, Ekaterini ^a   Tiniakos, Dina ^a   Pectasides, Dimitrios ^a   Papatheodoridis, George V ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

breath test; fatty liver; steatohepatitis

Indexed keywords

AMINOPYRIDINE; CARBON 13; GALACTOSE; GALACTOSE C 13; N,N DIMETHYLAMINOPYRIDINE C 13; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREATH ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; LIVER FUNCTION TEST; LIVER HISTOLOGY; LIVER MICROSOME; MALE; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC FATTY LIVER DISEASE ACTIVITY SCORE; PRIORITY JOURNAL;

ADULT; AGED; AMINOPYRINE; BREATH TESTS; CARBON ISOTOPES; CROSS-SECTIONAL STUDIES; FATTY LIVER; FEMALE; GALACTOSE; HUMANS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; ROC CURVE; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84891545868     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0000000000000036     Document Type: Article

References (47)

1. Hepner GW, Vesell ES. Assessment of aminopyrine metabolism in man by breath analysis after oral administration of 14C-aminopyrine Effects of phenobarbital, disulfiram and portal cirrhosis. N Engl J Med. 1974;291:1384-1388.
2. Armuzzi A, Candelli M, Zocco MA, et al. Review article: breath testing for human liver function assessment. Aliment Pharmacol Ther. 2002;16:1977-1996.
3. Brockmoller J, Roots I. Assessment of liver metabolic function. Clinical implications. Clin Pharmacokinet. 1994; 27:216-248.
4. Reichen J. Assessment of hepatic function with xenobiotics. Semin Liver Dis. 1995;15:189-201.
5. Perri F, Pastore M, Annese V, et al. The aminopyrine breath test. Ital J Gastroenterol. 1994;26:306-317.
6. Irving CS, Schoeller DA, Nakamura KI, et al. The amino-pyrine breath test as a measure of liver function. A quantitative description of its metabolic basis in normal subjects. J Lab Clin Med. 1982;100:356-373.
7. Cuatrecasas P, Segal S. Mammalian galactokinase: developmental and adaptive characteristics in the rat liver. J Biol Chem. 1965;240:2382-2388.
8. Berge SM, Henderson NL, Frank MJ. First-order clearance of plasma galactose: the effect of liver disease. Gastroenterology. 1982;83:1090-1096.
9. 2. Gastroenterology. 1976;71:98-101.
10. 13C galactose breath tests. A sensitive test to measure liver function. Gut. 1998;43:S25-S26.
11. Mion F, Rousseau M, Scoazec JY, et al. [13C]-Galactose breath test: correlation with liver fibrosis in chronic hepatitis C. Eur J Clin Invest. 1999;29:624-629
12. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology. 1994;20:15-20.
13. Farrell GC, van Rooyen D, Gan L, et al. NASH is an inflammatory disorder: pathogenic, prognostic and therapeutic implications. Gut Liver. 2012;6:149-171.
14. Leclercq IA, Field J, Enriquez A, et al. Constitutive and inducible expression of hepatic CYP2E1 in leptin-deficient ob/ob mice. Biochem Biophys Res Commun. 2000;268:337-344.
15. Weltman MD, Farrell GC, Hall P, et al. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steato-hepatitis. Hepatology. 1998;27:128-133.
16. Caldwell SH, Swerdlow RH, Khan EM, et al. Mitochondrial abnormalities in non-alcoholic steatohepatitis. J Hepatol. 1999;31:430-434.
17. Vendemiale G, Grattagliano I, Caraceni P, et al. Mitochondrial oxidative injury and energy metabolism alteration in rat fatty liver: effect of the nutritional status. Hepatology. 2001;33:808-815.
18. Hashimoto T, Fujita T, Usuda N, et al. Peroxisomal and mitochondrial fatty acid beta-oxidation in mice nullizygous for both peroxisome proliferator-activated receptor alpha and peroxisomal fatty acyl-CoA oxidase. Genotype correlation with fatty liver phenotype. J Biol Chem. 1999;274:19228-19236.
19. Grattagliano I, Vendemiale G, Caraceni P, et al. Starvation impairs antioxidant defense in fatty livers of rats fed a choline-deficient diet. J Nutr. 2000;130:2131-2136.
20. James OF, Day CP. Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance. J Hepatol. 1998;29:495-501.
21. Ploeg RJ, D'Alessandro AM, Knechtle SJ, et al. Risk factors for primary dysfunction after liver transplantation- A multi-variate analysis. Transplantation. 1993;55:807-813.
22. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43:S99-S112.
23. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology. 2005;42:987-1000.
24. Tsochatzis EA, Papatheodoridis GV, Archimandritis AJ. Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy. Mediators Inflamm. 2009;2009:831670.
25. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;18:1221-1231.
26. Hug H, Strand S, Grambihler A, et al. Reactive oxygen intermediates are involved in the induction of CD95 ligand mRNA expression by cytostatic drugs in hepatoma cells. J Biol Chem. 1997;272:28191-28193.
27. Spycher C, Zimmermann A, Reichen J. The diagnostic value of liver biopsy. BMC Gastroenterol. 2001;1:12.
28. Giannini EG, Fasoli A, Borro P, et al. 13C-galactose breath test and 13C-aminopyrine breath test for the study of liver function in chronic liver disease. Clin Gastroenterol Hepatol. 2005;3:279-285.
29. Portincasa P, Grattagliano I, Lauterburg BH, et al. Liver breath tests non-invasively predict higher stages of nonalcoholic steatohepatitis. Clin Sci. 2006;111:135-143.
30. Park GJ, Wiseman E, George J, et al. Non-invasive estimation of liver fibrosis in non-alcoholic fatty liver disease using the 13 C-caffeine breath test. J Gastroenterol Hepatol. 2011;26: 1411-1416.
31. Schmilovitz-Weiss H, Niv Y, Pappo O, et al. The 13C-caffeine breath test detects significant fibrosis in patients with nonalcoholic steatohepatitis. J Clin Gastroenterol. 2008;42: 408-412.
32. Ilan Y. Review article: the assessment of liver function using breath tests. Aliment Pharmacol Ther. 2007;26:1293-1302.
33. Giannini E, Fasoli A, Chiarbonello B, et al. 13C-aminopyrine breath test to evaluate severity of disease in patients with chronic hepatitis C virus infection. Aliment Pharmacol Ther. 2002;16:717-725.
34. Banasch M, Ellrichmann M, Tannapfel A, et al. The non-invasive (13)C-methionine breath test detects hepatic mitochondrial dysfunction as a marker of disease activity in non-alcoholic steatohepatitis. Eur J Med Res. 2011;16: 258-264.
35. 14C-galactose breath test for evaluation of liver function in patients with chronic liver disease. Digestion. 1978;17:410-418.
36. Expert Panel on Detection, Evaluation, And the Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP). JAMA. 2001;285: 2486-2497.
37. Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94: 2467-2474.
38. Kleiner DE, Brunt EM, Van Natta M, et al. Nonalcoholic steatohepatitis clinical research network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313-1321.
39. Mion F, Geloen A, Rousseau M, et al. Mechanism of carbon tetrachloride autoprotection: an in vivo study based on 13C-aminopyrine and 13C-galactose breath tests. Life Sci. 1994;54: 2093-2098.
40. Ghoos Y. 13CO2-breath tests at the laboratory "digestion- absorption". Belgium: University Hospital Gasthuisberg Leuven; 1994:43-54.
41. Yoneda M, Mawatari H, Fujita K, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Liver Dis. 2008;40:371-378.
42. Feldstein AE, Wieckowska A, Lopez AR, et al. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology. 2009;50:1072-1078.
43. Papatheodoridis GV, Hadziyannis E, Tsochatzis E, et al. Serum apoptotic caspase activity in chronic hepatitis C and nonalcoholic fatty liver disease. J Clin Gastroenterol. 2010; 44:e87-e95.
44. Park GJ, Katelaris PH, Jones DB, et al. The C-caffeine breath test distinguishes significant fibrosis in chronic hepatitis B and reflects response to lamivudine therapy. Aliment Pharmacol Ther. 2005;22:395-403.
45. Mion F, Rousseau M, Brazier JL, et al. Human hepatic macrovesicular steatosis: a noninvasive study of mitochondrial ketoisocaproic acid decarboxylation. Metab Clin. 1995;44: 699-700.
46. Herold C, Ganslmayer M, Ocker M, et al. Inducibility of microsomal liver function may differentiate cirrhotic patients with maintained compared with severely compromised liver reserve. J Gastroenterol Hepatol. 2003;18:445-449.
47. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. 2001;121: 91-100.